Groundbreaking pan-cancer screening study published
Solna, Sweden – May 29, 2018 –Baseline data from iCellate’s groundbreaking screening study – Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2) – has been published in the May issue of the journal Disease Markers. iCellate, in collaboration with Hospital Nacional Arzobispo Loayza in Lima, has conducted an all-comers, single center study in a high-risk population (smokers, cancer heredity, hepatitis B or positive PSA) of 3388 subjectively healthy individuals to investigate if screening for CTC (circulating tumor cells) in